French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

New research shows some gut bacteria mimic myelin, tricking immunity to attack nerves and worsen MS. Non-inflammatory ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

Elsa Mendoza navigates life with multiple sclerosis, using a wheelchair while her son, Fernando, excels as a quarterback ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

Multiple Sclerosis Awareness Month highlights education, advocacy, research support, and ways to uplift the MS community throughout March.

The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

Children with MS who have more paramagnetic rim lesions, or chronic inflammation, tend to show faster declines in brain ...

Dec 15 () - Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to ​a U. regulatory ...

Tolebrutinib received provisional approval in the United Arab Emirates in July 2025 for non-relapsing secondary progressive ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...